Publication: 859

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Citation:: J Clin Oncol vol 29 (17) 2342-2349

Year:: 2011
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 425 528 784
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: R01 CA095614, R01 CA095614-09, R01-CA095614, U01-CA114722, U10-CA076001, U24-CA114736

Corr. Author:
Authors:: Matthew J. Ellis Vera J. Suman Jeremy Hoog Li Lin Jacqueline Snider Aleix Prat Joel S. Parker Jingqin Luo Katherine DeSchryver D. Craig Allred Laura J. Esserman Gary W. Unzeitig Julie Margenthaler Gildy V. Babiera P. Kelly Marcom Joseph M. Guenther Mark A. Watson Marilyn Leitch Kelly Hunt John A. Olson

Networks:

Study: ACOSOG-Z1031
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: